And so say all of us. Hey
@daicosisgod I remember you posting on a couple of occasions that you were drawn back into Mayne Pharma because you thought Nexstellis was a superior product (safety wise) to other oral contraceptives and board member Prof. Robinson gave a substantial answer to a question posed at the last AGM.
I think that finally, finally we may be seen a demonstration that this is the way to market this product. I have noticed in all the presentations this year there's now either a slide or commentary on the safety benefits to womem's bodies, effects on cholesterol, acne, weight gain, breast tenderness, liver kidney function, endometriosis etc. This should have been obvious from the start.
We are now directly comparing Nextstellis to Yaz and promoting its' safer benefits. They both have exactly the same components, but Nextstellis has Estetrol (the native estrogen) and Yaz has a synthetic Estrogen .There's a number of post-marketing studies being conducted (some with as many as 70,000 participants) but large studies won't be completed for a few years but anecdotally post-marketing data is starting to come through.
To put it in economic terms, Yaz has annual sales of US$700M of the total US oral contraceptive market of about US$3.7Billion, if we are able to cut through against Yaz we will also cut through the rest of the oral contraceptive market.
I am hoping that the new WH leadership and renewed focus will do that.
Cheers
As a post note, I don't think there's anything within the last few reports that would cause the share price decline we have seen and is not reflective of what is going on inside the company. August report will reveal all.
(20min delay)